Unjoni Ewropea - Malti - EMA (European Medicines Agency)

santen oy - latanoprost, netarsudil mesilate - glaucoma, open-angle; ocular hypertension - oftalmoloġiċi - roclanda is indicated for the reduction of elevated intraocular pressure (iop) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient iop reduction.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

gedeon richter plc. - drospirenone, estetrol monohydrate - contraceptives, oral - - ormoni tas-sess u modulaturi ta ' l-ġenitali-sistema, - oral contraceptive.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - - ormoni tas-sess u modulaturi ta ' l-ġenitali-sistema, - kontraċezzjoni orali. the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4. 3 and 4.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

teva pharma b.v. - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - kombinazzjonijiet - clopidogrel / acetylsalicylic acid teva huwa indikat għall-prevenzjoni ta 'avvenimenti aterotrombotiċi f'pazjenti adulti li diġà qegħdin jieħdu clopidogrel u acetylsalicylic acid (asa). clopidogrel/acetylsalicylic acid teva huwa kombinazzjoni b'doża fissa tal-prodott mediċinali għall-kontinwazzjoni tat-terapija:mhux elevazzjoni tas-segment st sindromu koronarju akut (anġina instabbli jew mhux‑mewġa‑q infart mijokardijaku) li jinkludu pazjenti fi proċess li titpoġġa stent wara koronarju perkutanju interventionst elevazzjoni tas-segment infart mijokardijaku akut fil-medikament pazjenti kkurati b'eliġibbli għat-terapija trombolitika.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig  - axitinib - karċinoma, Ċellula renali - inibituri tal-proteina kinase - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

alnylam netherlands b.v. - patisiran sodium - amilojdożi, familjali - drogi oħra tas-sistema nervuża - onpattro huwa indikat għall-kura ta ' transthyretin medjat amilojdożi (hattr amilojdożi) f'pazjenti adulti bil-istadju ta'l-1 jew l-istadju 2 polinewropatija.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

eisai gmbh - alitretinoin - sarcoma, kaposi - aġenti antineoplastiċi - panretin gel hija indikata għat-trattament topiku ta ' leżjonijiet fil-ġilda f'pazjenti b'akkwistat-immuni-defiċjenza tal-syndrome (aids) relatati mal-sarkoma ta'kaposi (ks) meta: - leżjonijiet ma jkunux ulcerated jew lymphoedematous, u;it-trattament tal-vixxri ks ma hija meħtieġa, u; - leżjonijiet huma li ma jkunux qed jirrispondu għal sistemika-terapija kombinata antiretrovirali, u;ir-radjuterapija jew kimoterapija mhumiex xierqa.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - sklerosi multipla - immunosuppressanti selettivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 u 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosoppressanti - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 u 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. (miol) - febuxostat - gotta - preparazzjonijiet antigout - 80 mg saħħa:it-trattament ta'iperuriċemija kronika f'kundizzjonijiet fejn il-depożizzjoni ta ' urate diġà seħħet (inkluż passat, jew preżenza ta tophus u/jew l-artrite tal-gotta). adenuric huwa indikat fl-adulti. 120 mg saħħa:adenuric huwa indikat għat-trattament ta'iperuriċemija kronika f'kundizzjonijiet fejn il-depożizzjoni ta ' urate diġà seħħet (inkluż passat, jew preżenza ta tophus u/jew l-artrite tal-gotta). adenuric huwa indikat għall-prevenzjoni u t-trattament ta'l-iperuriċemija f'pazjenti adulti li għaddejjin minn kimoterapija għal tumuri malinni ematoloġiċi fil-intermedjarju u għoli tar-riskju tas-sindrome tal-lisi tat-tumur (tls). adenuric huwa indikat fl-adulti.